CRFs were collected from 749 patients at 98 institutions nationwide (Fig. 1). Of these, 732 patients were included in the safety analysis set, excluding those who fell under “breaches of contract” and “protocol deviations”. All 732 patients were included in the efficacy analysis set. The mean (±standard deviation) observation period was 64.9 ± 73.8 days [median (range) 31.0 (1–531) days], regardless of continuation or discontinuation of prasugrel treatment.Fig. 1Patient disposition. ACS acute coronary syndrome